A pharmaceutical organization specialising in the development of medicines for supportive care.

We believe APD403 is an excellent anti-vomiting agent and a fantastic anti-nauseant, thereby having the potential to make a significant contribution to cancers care.’ APD403 provides the marketed dopamine D2 /D3 antagonist amisulpride for the new currently, patent-protected, use of administration of CINV. The active component is also being developed as APD421 for preventing post-operative nausea & vomiting , with two pivotal Phase III clinical studies having been initiated recently.. Acacia Pharma starts APD403 Phase II study to prevent chemotherapy-induced nausea & vomiting Acacia Pharma, a pharmaceutical organization specialising in the development of medicines for supportive care, announces the initiation of a Phase II research of APD403 in the prevention of chemotherapy-induced nausea & vomiting .Kaiser Family members Foundation. Kaiser Health News, an editorially independent news service, is an application of the Kaiser Family members Foundation, a nonpartisan health care policy research business unaffiliated with Kaiser Permanente.

50 percent of Americans have gene that affects how body burns sugar A recent study by a Saint Louis University researcher confirms results that about half of the U.S. Population has a version of a gene that causes them to metabolicly process food differently, putting them at greater risk of developing diabetes. Edward Weiss, Ph.D., associate professor of dietetics and nourishment at Doisy University of Wellness Sciences at Saint Louis University, looked at a comparatively common version of a gene called FABP2, which is involved in the absorption of fats from food.